Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday. One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to AstraZeneca for $200 …
Source: Endpoints News
You may also like
Stem Cell Therapy Shows Promise in First Human...
Ag Genomics Begins to Bear Fruit
StockWatch: Insilico Projects Profit, Revenue Leaps as...
Macrophage Membrane-Derived Nanoparticles Shows...
[Podcast] From Protocol to Patient: Inside Clinical...
KKR-backed Allyntra debuts to serve medtech industry...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.